针对营收下滑的原因，一品红表示，主要是受市场环境变化影响销售不及预期所致。 北京商报讯（记者 丁宁）8月21日晚间，一品红（300723）披露2025年半年报显示，公司上半年实现营 业收入5.84亿元，同比下降36.02%；归属净利润为-7354.22万元，同比由盈转亏。 ...

Core Insights - Yipinhong Pharmaceutical Group Co., Ltd. reported a steady development in the first half of 2025, focusing on children's medicine, chronic disease drugs, and innovative drugs [1] - The company achieved a revenue of 584 million yuan and a net profit attributable to shareholders of -73.54 million yuan in the first half of 2025 [1] - Total assets reached 4.981 billion yuan, reflecting a 13.1% increase compared to the beginning of the period [1] Financial Performance - Revenue for the first half of 2025 was 584 million yuan [1] - Net profit attributable to shareholders was -73.54 million yuan [1] - Total assets as of June 30, 2025, were 4.981 billion yuan, up 13.1% from the start of the year [1] R&D and Product Development - The company invested approximately 94.201 million yuan in R&D, accounting for 16.14% of total revenue [1] - A total of 10 new registration certificates were obtained, maintaining a leading position among pharmaceutical companies [1] - The company introduced 2 CMO projects and 1 equity investment project during the reporting period [1] Innovative Drug Progress - The innovative drug AR882 (Dezhuobote) is a selective URAT1 inhibitor with three indications: lowering blood uric acid for gout treatment, dissolving gout stones, and treating chronic kidney disease [2] - The global pivotal Phase III REDUCE 2 trial completed patient enrollment in March 2025, and the REDUCE 1 trial surpassed 50% enrollment by June 2025 [2] - The company acquired 15.25% of the equity in its subsidiary Guangzhou Ruianbo, increasing its ownership of AR882 in China to 100% [2]

Core Insights - The company Yipinhong (300723) reported a revenue of 584 million yuan and a net profit attributable to shareholders of -73.54 million yuan for the first half of 2025, indicating a focus on children's medicine, chronic disease drugs, and innovative drugs [1] - As of June 30, 2025, the company's total assets reached 4.981 billion yuan, an increase of 13.10% compared to the beginning of 2025 [1] - The company achieved significant progress in innovative drugs, obtaining 10 drug registration approvals in the first half of the year, with the global development of the innovative drug AR882 accelerating [1][2] Financial Performance - The company's revenue for the first half of 2025 was 584 million yuan, with a net loss of 73.54 million yuan [1] - Research and development investment for the first half of 2025 was approximately 94.21 million yuan, accounting for 16.14% of the company's revenue [1] Product Development - Yipinhong currently holds 200 drug registration approvals, including 87 national medical insurance varieties and 26 national basic drug varieties [2] - In the children's medicine sector, the company has 27 registration approvals covering common diseases such as respiratory, anti-infection, anti-allergy, and digestive issues [2] - In the chronic disease drug sector, there are 67 registration approvals addressing cardiovascular, urinary, and digestive system diseases [2] - The company also received 5 new product approvals in other therapeutic areas during the reporting period, expanding its product portfolio [2] Innovative Drug AR882 - AR882, developed in collaboration with Arthrosi, is a first-class innovative drug aimed at treating gout and gout stones by inhibiting uric acid reabsorption [2] - The drug's research results were presented at the 2025 European League Against Rheumatism (EULAR) conference, gaining international attention [2] - The global pivotal phase III REDUCE2 trial for AR882 has completed enrollment of all patients, while the REDUCE1 trial has surpassed 50% patient enrollment as of June 2025 [2]

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. has completed the enrollment of all participants in the global Phase III clinical trial for AR882, a novel drug for the treatment of gout and gout stones, developed in collaboration with Arthrosi Therapeutics, Inc. [1] Group 1 - AR882 (generic name: Deuricostat) is a first-class innovative drug that acts as a selective uric acid transporter (URAT1) inhibitor, aimed at normalizing uric acid salt excretion in urine and lowering serum uric acid (sUA) levels [1] - The company indirectly holds a 22.52% stake in Arthrosi [1] - The company, through its wholly-owned subsidiary Guangzhou Ruian Bo Pharmaceutical Technology Co., Ltd., holds 100% of the marketing authorization and all commercialization rights for AR882 in the Chinese region, including mainland China, Hong Kong, Macau, and Taiwan [1]

Core Viewpoint - The company reported a decline in net profit for the first half of 2025, while continuing to expand its research pipeline in children's medicine, chronic disease drugs, and innovative drugs [1][2]. Group 1: Financial Performance - In the first half of 2025, the company achieved an operating income of 584 million yuan, with a net profit attributable to shareholders of -73.54 million yuan [1]. - The company's self-research investment was approximately 94.21 million yuan, accounting for 16.14% of its operating income [2]. Group 2: Product Development and Approvals - The company obtained 10 new registration certificates, maintaining a leading position in the pharmaceutical industry for new approvals [2]. - The company has a total of 200 drug registration certificates, including 87 national medical insurance varieties and 26 national basic drug varieties [2]. - In addition to children's and chronic disease drugs, the company also received approvals for 5 new products in other therapeutic areas [3]. Group 3: Innovative Drug Development - The innovative drug AR882, a selective uric acid transporter (URAT1) inhibitor, has shown significant progress in clinical trials, with all participants enrolled in the global phase III trials [4]. - AR882 has demonstrated superior efficacy and safety compared to existing therapies for gout patients, with significant reductions in uric acid levels and gout stone burden [4]. - The company acquired 100% domestic rights to AR882 by purchasing a minority stake from a subsidiary, enhancing its competitive advantage [5].

自愿披露关于痛风创新药 AR882 全球Ⅲ期临床试验完成全部受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1.公司合作在研的创新药 AR882 尚需在国内外开展Ⅲ期临床研究并经药品 审评部门审批通过后，方可上市销售,能否通过监管部门的最终批准、获批上市 及上市时间具有不确定性。AR882 目前尚未实现上市销售，未产生销售收入，对 公司近期业绩不会产生重大影响。 2.AR882 全球Ⅲ期临床试验进展对公司近期业绩不会产生重大影响。敬请广 大投资者理性投资，注意风险。 近日，一品红药业集团股份有限公司（以下简称"公司"）参股公司 Arthrosi Therapeutics,Inc.（以下简称"Arthrosi"）组织开展的 AR882（通用名：氘泊替 诺雷）胶囊用于治疗痛风和痛风石全球关键性Ⅲ期临床试验已完成全部受试者入 组。现将主要情况公告如下： 证券代码：300723 证券简称：一品红 公告编号：2025-056 一品红药业集团股份有限公司 公司始终秉承创新发展理念，坚持医药技术创新与高端药品研发，通过自主 研发、合资合作开 ...

智通财经APP讯，一品红(300723.SZ)发布2025年半年度报告，该公司营业收入为5.84亿元，同比减少 36.02%。归属于上市公司股东的净亏损为7354.22万元。归属于上市公司股东的扣除非经常性损益的净 亏损为1.08亿元。基本每股亏损为0.1628元。 2025上半年公司自主研发投入约9,420.10万元，占公司营业收入的16.14%。2025年至今公司新增产品注 册批件10个。 ...

一品红药业集团股份有限公司 按照《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》(证监会公告[2022]26 号文）及其他相关规定，公 司 2025 年半年度非经营性资金占用及其他关联资金往来情况如下表所示： 上市公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | 单位：元 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 占用方与上 | 上市公司核 | | 2025 年半年度占 | | 2025 年半年度 | | | | | 非经营性资 | 资金占用方名称 | | 市公司的关 | 2025 年半年度期 算的会计科 | | 年度占用 用累计发生金额 | | 2025 年半年度期 偿还累计发生 | 占用形 | 占 | | 用性质 | | | | | | | | | | | | 金占用 | | | | 初占用资金余额 | | 资金的利 | | 末占用资金余额 | 成原因 | | | | | 联关系 | 目 | | （不含利息） | ...

证券代码：300723 证券简称：一品红 公告编号：2025-052 一品红药业集团股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一品红药业集团股份有限公司（以下简称"公司"）第四届董事会第十一次 会议于 2025 年 8 月 20 日 15：00 以现场结合通讯表决方式召开。本次会议通知 已于 2025 年 8 月 8 日以电话或电子邮件等方式向全体董事发出。会议由董事长 李捍雄先生主持，会议应到董事 5 人，实到董事 5 人。公司监事、高管列席会议。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规以 及《一品红药业集团股份有限公司章程》的有关规定。 二、董事会会议审议情况 公司 2025 年半年度报告所载资料内容符合法律、行政法规、中国证券监督 管理委员会和深圳证券交易所的相关规定，报告内容真实、准确、完整，不存在 任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）上披露的 《2025 年 ...

证券代码：300723 证券简称：一品红 公告编号：2025-053 一品红药业集团股份有限公司 第四届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 一品红药业集团股份有限公司（以下简称"公司"）第四届监事会第十次会 议于 2025 年 8 月 20 日 15：30 以现场结合通讯表决方式召开。本次会议通知已 于 2025 年 8 月 8 日以电话或电子邮件等方式向全体监事发出。会议由监事会主 席黄良雯女士主持，会议应到监事 3 人，实到监事 3 人，公司高管列席会议。本 次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法规以及 《一品红药业集团股份有限公司章程》的有关规定。 二、监事会会议审议情况 监事会认为：公司董事会编制和审核的公司 2025 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）上披露 ...